Source comparison
Does MOTS-c Help Fat Loss Research: Comparison of Mitochondrial Peptides
Different mitochondrial-targeting peptides operate through distinct mechanisms. Comparing their fat loss pathways clarifies where MOTS-c fits within metabolic research. MOTS-c AMPK activation, GLUT4 translocation Indirect via increased fatty acid oxidation in
This comparison does not assign a generated winner or score.
- Different mitochondrial-targeting peptides operate through distinct mechanisms. Comparing their fat loss pathways clarifies where MOTS-c fits within metabolic research.
- MOTS-c
- AMPK activation, GLUT4 translocation
- Indirect via increased fatty acid oxidation in muscle and improved insulin sensitivity
- 4–6 hours
- Skeletal muscle > liver > adipose
- Preclinical (animal models, limited human pilots)
- Humanin
- Cytoprotection, STAT3 signaling
- Indirect via reduced inflammation and improved metabolic flexibility
- 2–3 hours
- Pancreatic beta cells, cardiovascular tissue
- Preclinical
- SS-31 (Elamipretide)
- Cardiolipin binding, mitochondrial cristae stabilization
- None direct. Improves ATP production efficiency but no lipid metabolism modulation
- 3–5 hours
- Cardiac and renal mitochondria
- Phase II/III clinical trials (heart failure, mitochondrial disease)
- AOD-9604
- hGH fragment, lipolytic signaling
- Direct lipolysis stimulation without GH receptor activation
- 30–60 minutes
- Adipose tissue selective
- Withdrawn from development (failed Phase II efficacy)
- Survodutide
- Dual GLP-1/glucagon receptor agonist
- Direct appetite suppression + increased energy expenditure via glucagon thermogenesis
- 168 hours (7 days)
- GI tract, hypothalamus, liver, adipose
- Phase III trials ongoing (2024–2026)
- Metabolic reprogramming without appetite suppression
- Fat oxidation preference shift. Requires caloric deficit or exercise for maximal fat loss
- Muscle-dominant effect
- Early human trials
- The comparison underscores a critical distinction: MOTS-c doesn't suppress appetite (unlike GLP-1 agonists) and doesn't directly stimulate lipolysis (unlike beta-agonists or hGH fragments). Its value in fat loss research lies in metabolic substrate switching. Making the body preferentially burn fat when energy is needed, rather than forcing fat release or reducing intake.